Lu

Lutetium

Investing

Investing in Lutetium

The investment landscape for Lutetium offers multiple avenues for exposure, ranging from equities of mining and processing companies to ETFs and commodity instruments. With prices currently around 900-1,400 $/kg oxide, the Lutetium market reflects both structural demand growth and ongoing supply chain challenges.

Current Price

900-1,400

$/kg oxide

Benchmark

Asian Metals

Supply Risk

High

Investment factor

Criticality

High

Key Companies

The Lutetium value chain includes these publicly listed and major private companies:

China Southern Rare Earth Group

Producer
China

Primary global source of separated lutetium

Siemens Healthineers

Major consumer SHL.DE
Germany

Major PET scanner manufacturer using LSO/LYSO scintillation crystals containing lutetium

GE HealthCare

Major consumer GEHC
United States

Produces PET scanners using lutetium-based scintillator detectors

Novartis

Consumer NVS
Switzerland

Markets Pluvicto (lutetium-177 PSMA), a radioligand therapy for metastatic prostate cancer approved in 2022

Market Drivers

Lutetium investment performance is driven by demand growth in pet scan detectors and petroleum refining catalysts, supply concentration in China (95% share), new project development timelines, and government policies including export restrictions and strategic stockpiling programs.

Risk Factors

Investing in Lutetium carries risks including commodity price volatility (see price history below), geopolitical risk in producing regions, regulatory uncertainty, and potential substitution. The high supply risk can create both opportunities from supply-driven price spikes and risks from sudden policy interventions.

Recent Price History

Lutetium oxide is priced at $800-1,200/kg, making it the most expensive rare earth element by weight due to its extreme scarcity (heaviest and rarest lanthanide). The market is tiny (~10 tonnes/year) with no exchange trading. Medical demand for PET scanner scintillators and the rapidly growing Lu-177 radiopharmaceutical market are the primary price supports. The emergence of Lu-177-based cancer therapies (Pluvicto) has created a new high-value demand stream that could strain the already minimal supply.

Return to the Lutetium hub page or browse the full Mineral Library.